IDOGEN

Idogen

Market Cap 54.2M

Idogen is a Swedish biotech company developing tolerogenic cell therapy to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues. The company was founded in 2008 and has been listed on Spotlight since its IPO in 2015. Idogen has two projects in its pipeline and is currently in the process and production optimization stage and expects to enter clinic by the first half of 2020. The lead project is IDO 8, being developed for hemophilia A patients with inhibitors to factor VIII replacement therapy. Follow-on project IDO T is being developed for kidney transplant recipients to avoid graft rejection. Idogen has been granted orphan drug designation for IDO 8 in the EU and the company has received a Horizon 2020 grant that contributes funding for preclinical development and the phase I/IIa study in hemophilia A. Idogen currently has no income and there is still some time before a project could enter clinic. And while Idogen could, given the limited indication sizes, bring the IDO 8 project to late-stage clinical development or even commercialization, cell therapies are complicated to develop, and clinical and CMC costs will be significant. Thus, we believe that Idogen could seek out-licensing opportunities or other project deals prior to market approval if early clinical data is very good.

+ more
Today
Day High
2.60
2.6
Day Low
2.60
Day Open
2.60
Prev Close
2.61
VWAP
2.6
Volume
4K
Turnover
0.010M
Top Broker
AVA
VWAP
2.7
Avg Volume
19K
Avg Turnover
0.053M
Top Brokers
AVA/SHB
VWAP
2.6
Avg Volume
19K
Avg Turnover
0.052M
Top Brokers
AVA/NON
VWAP
2.5
Avg Volume
24K
Avg Turnover
0.059M
Top Brokers
AVA/NON
52 week summary
Price Range
2.1
Last
6.0
Beta
N/A
Market Cap
54.2M
Total Return
-55.8%
Trailing P/E
N/A
Div Yield
0.0%
Shares Outstanding
20.8M
Stock Exchange
Spotlight Stock Market
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months -37.5%
Change 12 Months -55.7%
Volume Trend
Average Volume 10 vs 60 Days -45.0%
Price VS
52 Week High -56.7%
50 Day Moving Average -0.1%
200 Day moving Average -32.2%

Add article markers

Compare Idogen to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
Last updated: 2018-06-05 Source: Redeye
Major Owners Equity Votes
HCN Group AB 11.0%
11.0%
Avanza Pension 5.2%
5.2%
Ventac Holding (Cyprus) Ltd 4.3%
4.3%
Nils Berntsson 3.4%
3.4%
Olov Sjögren 3.3%
3.3%
Leif-Göran Salford 3.2%
3.2%
Charlotte Widing 1.8%
1.8%
Nordnet Pensionsförsäkring 1.8%
1.8%
Mikael Lönn 1.7%
1.7%
Henrik Magne Wilhelm Widegren 1.4%
1.4%
Last updated: 2018-06-05 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
0 Purchases
0
0 Sales
0
Last 24 weeks
0 Purchases
0
0 Sales
0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Insider trades are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2015
  •  
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 0.0
  •  
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  •  
  • 0.0%
  • 0.0%
  • 0
  • 0
  • 0.0
  • 2015
  •  
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  •  
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q4
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016
  •  
  • 0.0%
  • -135.3%
  • 0.0%
  • -314,575.0%
  • -314,575.0%
  • -314,975.0%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 0.0
  •  
  • -18.5
  • 0.0
  • 0.0
  • 0.0
  • -4,625.5
  • 1.5
  • 1.5
  • 0.0
  •  
  • 90.0%
  • 0.0%
  • -19
  • 0
  • 0.0
  • 2016
  •  
  •  
  • 19
  • 0
  • 0
  • 0
  • 19
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2
  • 0
  • 2
  • 0
  • 21
  •  
  •  
  • 0
  • 1
  • 1
  • 2
  • 0
  • 0
  • 0
  • 2
  • 0
  • 0
  • 19
  • 0
  • 19
  • 21
  • 2016
  • 0
  • -13
  • 0
  • -13
  • 0
  • -13
  • 0
  • -13
  • 2
  • -2
  • -13
  • 2016 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q4
  • 0
  • -13
  • -13
  • 0
  • 0
  • 0
  • -13
  • 0
  • 0
  • 0
  • -13
  • 0
  • -13
  • 2017
  •  
  • -72.9%
  • -72.8%
  • -22,658.5%
  • -532,475.0%
  • -532,475.0%
  • -533,050.0%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 0.0
  •  
  • -36.9
  • 0.0
  • 0.0
  • 0.0
  • -9,236.3
  • 1.7
  • 1.7
  • 0.0
  •  
  • 90.3%
  • 0.0%
  • -37
  • 3
  • 0.0
  • 2017
  •  
  •  
  • 37
  • 0
  • 0
  • 1
  • 38
  •  
  • 3
  • 0
  • 0
  • 0
  • 0
  • 3
  • 0
  • 6
  • 0
  • 44
  •  
  •  
  • 0
  • 3
  • 1
  • 4
  • 0
  • 0
  • 0
  • 4
  • 0
  • 0
  • 40
  • 0
  • 40
  • 44
  • 2017
  • 0
  • -21
  • 0
  • -21
  • 0
  • -21
  • 0
  • -21
  • 1
  • -4
  • -24
  • 2017 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2017 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2017 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2017 Q4
  • 0
  • -21
  • -21
  • 0
  • 0
  • 0
  • -21
  • 0
  • 0
  • 0
  • -21
  • 0
  • -21
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2020 E
  • 2020 E
  • 2020 E
  • 2020 E

Estimated Values are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2018-06-05 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye